← Surfer · Sage hub

Sage — Signals: Metabolic Hypothesis of Cell Signaling Dysfunction + Energy-Signal Cluster

Named “hormone imbalances,” resistances, and peptide programs are treated first as long-running expressions of how distributed chemical coordination recalibrates when cellular energy transduction is strained. This page adds the energy-signal cluster: adenosine as high-frequency energy-stress dashboard, caffeine as temporary brake override, nicotine as demand-side cholinergic amplifier, endocannabinoids as conservation / recovery / mitochondrial throttle — and alcohol only as redox-toxin adjacency, not a Surfer drinking protocol. Stay monist: Shore / Surf Judge language names orientation inside one field — not a second “mind stuff” beside mitochondria, and not a morality play in which insulin, cortisol, TSH, caffeine, or nicotine invent evil independent of cellular fuel handling.

1. Introduction: one engine, many named signal diseases

Chronic diseases of modernity share a common upstream driver in this series: persistent cellular bioenergetic insufficiency rooted in mitochondrial dysfunction. Prior essays tracked that driver through atherosclerosis, cancer, aging, immune dysfunction, and organ archetypes. Here the same premise extends to cell signaling — the distributed chemical communication networks encompassing endocrine (hormonal), paracrine, autocrine, mitocrine (mitochondria-derived), peptide, and intracellular second-messenger systems — and to the energy-signal cluster that reports charge across timescales.

What conventional models label as “resistance,” “dysregulation,” “hyper- or hyposecretion,” or “imbalance” is better understood, on this map, as higher-order compensatory mechanisms attempting to restore level 0–1 persistence when primary cellular energy production falters or when fuel utilization is impaired. Level 0–1 persistence means the fundamental cellular striving for persistence: adequate ATP production, redox balance, and metabolic homeostasis centered on mitochondria as the interface. Signaling operates as a higher-level (roughly level 2–4) multi-cellular and systemic coordination layer. It senses energy charge (AMPK), redox (Nrf2/Keap1), and metabolites; integrates nutrient availability, circadian phase, and stress; and orchestrates mobilization (catecholamines, glucagon, cortisol), conservation (thyroid downregulation, leptin resistance in some contexts), resource direction (insulin, IGF-1), growth/repair/reproduction only when surplus exists, and local coordination (growth factors, cytokines, myokines, adipokines).

Acute, context-appropriate activation is typically adaptive and self-resolving once persistence is restored. Chronic persistence, resistance, or inappropriate tone reflects failed resolution secondary to ongoing level 0–1 deficit — not a primary “endocrine disorder” or receptor defect as the whole story. Dashboard-discipline applies: map ≠ terrain. Panel numbers, receptor occupancy, and Surfer “stack” screenshots are readings into an engine story — not the disease itself.

2. Conventional endocrinology: powerful axis tools, incomplete upstream story

On Sage — Endocrinology and metabolism.

3. Mitochondria as signaling hubs and mitocrine communication

Mitochondria are not merely ATP factories. They generate and interpret signals: physiological ROS as second messengers (Nrf2, HIF, NF-κB) versus pathological ROS from impaired ETC or cardiolipin peroxidation; TCA intermediates as signaling metabolites (succinate/GPR91, α-ketoglutarate epigenetics, itaconate/Nrf2, acetyl-CoA and NAD+/NADH ratios reporting energy status to sirtuins, PARPs, histone acetylation); mitochondrial-derived peptides / mitokines (MOTS-c, humanin, SHLPs) whose production is itself bioenergetically sensitive; calcium buffering and MAMs integrating Ca²⁺, lipid, and ROS fidelity; contacts, vesicles, and mtDNA release as DAMPs.

When level 0–1 capacity declines, mitocrine outputs distort: insufficient adaptive signals, excessive damage signals, loss of fine metabolite gradients. Higher endocrine and paracrine systems then alter setpoints, sensitivities, or ligand concentrations to keep the organism alive under energetic duress. That is the substrate of chronic “signaling dysfunction.” Mitokines named here are essay biology — not a Surfer peptide catalog.

4. Endocrine axes as compensation for cellular energy insufficiency

On Sage — Endocrinology and metabolism.

5. Paracrine, autocrine, and local tissue signaling

Myokines from contracting muscle signal to adipose, liver, pancreas, and brain; beneficial profiles require muscle mito capacity and blunt in sedentary or energy-deficient states. Adipokine shifts in hypoxic, inefficient adipose promote systemic IR and inflammation. Endothelial NO (eNOS — energy and redox sensitive) fails with endothelial mito dysfunction, contributing to stiffness and hypertension as attempts to maintain perfusion when microcirculatory efficiency falls — developed as flux-matching grammar in §5b and on Cardiac. Hepatokines link liver to IR. Under chronic level 0–1 stress these local loops lock maladaptive setpoints until the primary deficit is addressed. Immune cytokine milieus sit on the same engine: unresolved inflammation as compensation that never stood down — see Sage — Immune.

5b. Nitric Oxide as flux-matching signal

Primary depth for vascular/cardiac phenotypes lives on Sage — Nitric Oxide. This Signals nest only places NO inside the energy-signal hierarchy: a short-lived gas that matches delivery, consumption, and conduit protection to mitochondrial demand — sibling grammar to adenosine (brake), insulin (substrate shove), and serotonin (oxygen/carbon allocation; see Sage — Serotonin).

Hypothesis (three acts, not a protocol):

• Delivery. Working tissue opens arterioles; laminar shear recruits eNOS; feed arteries dilate so the tree scales together. Training is chronic instruction that keeps the delivery system competent — not merely calorie burn.
• Rationing. Nanomolar NO partially and reversibly brakes cytochrome c oxidase so proximal mitochondria do not monopolize oxygen; deep tissue can still run oxphos. Delivery and rationing are one system.
• Conduit protection. Tonic eNOS-derived NO restrains adhesion, thrombosis, permeability, and smooth-muscle overgrowth. Loss of that tone is why NO sits at the beginning of plaque biology rather than only at its end.

Acute matching vs scar. Acute NO-driven conductance is hormesis: pulsed, reversible, load-meeting. Left on as standing operating procedure, the same loops remodel tissue and reset set-points — plaque, stiff artery, vasculogenic erectile failure, hypertension-as-scar, insulin-resistance tolerance, and related siblings. That is path dependence, not a second ontology beside mitochondria. PDE5 inhibitors amplify existing cGMP; they do not manufacture NO. This page does not invent a PDE5 prevention stack, nitrate schedule, or Surfer “NO booster” protocol.

Endothelial NO already appeared in §5 as energy- and redox-sensitive. The 2.0 fold sharpens the claim: NO is not merely a blood-pressure gadget or a missing molecule to supplement. It is the local language of demand–delivery–consumption negotiation. When bioavailability is adequate and eNOS remains coupled, high energy flux is possible without proportional damage. When it is lost or uncoupled, the cell meets the same upstream deficit named across aging, cancer, and atherosclerosis essays — insufficient oxidative ATP relative to the cost of remaining ordered.

Cross-links: Nitric Oxide · Eye (ocular shear–eNOS / glaucoma compartments in the Sage essay) · Serotonin · Thyroid / Temperature.

6. Acute adaptive vs chronic persistent signaling: resolution failure

Proper acute responses are energy-intensive, purposeful, and self-limiting. Catecholamine surge mobilizes fuels; if mitochondria oxidize them, ATP rises and feedback closes the loop. Insulin peaks drive uptake and storage; resolution follows utilization. Growth-factor pulses support repair when surplus allows anabolism. Adenosine rises with ATP hydrolysis and enforces a brake; recovery clears the pool. Nicotinic pulses amplify demand then release; endocannabinoid tone supports conservation and sleep-window entry when intermittent.

Modern environments prevent closure: oxidized lipids damaging mito membranes, artificial light and circadian misalignment impairing biogenesis and hormone rhythms, chronic low-level endotoxemia, nutrient-poor ultra-processed diets lacking ETC and antioxidant cofactors, continuous stimulant occupancy without recovery windows. Demand for compensatory signaling stays on (sympathetic tone, hyperinsulinemia, cortisol, altered thyroid economy, receptor desensitization) while resolution machinery itself is energy-dependent (receptor trafficking, phosphatases, negative-feedback transcription, clearance, mitophagy–biogenesis coupling). The epidemic picture of “endocrine dysfunction” and “stimulant dependence” is that stuck loop.

7. Multi-timescale energy dashboards

The energy-signal trio + caffeine essay share one hierarchy with Compensatory-cascade and Dashboard-discipline:

• Adenosine / AMP / AMPK — high-frequency, seconds-to-hours energy-stress dashboard and brake. Reports falling energy charge; initiates mitophagy/biogenesis programs when recovery is allowed.
• Cortisol — daily-wavelength waveform. Function (ATP capacity) shapes form (curve amplitude and timing); treating the curve as the disease without the engine is dashboard capture.
• Nicotinic cholinergic interface — demand-side amplifier of arousal, thermogenesis, anti-inflammatory tone, and capacity programs — adaptive only when intermittent and followed by recovery.
• Endocannabinoid / mtCB1 — conservation, storage allocation, protective dampening, and recovery-window support — adaptive when intermittent; chronic tone locks anabolic drive and throttles biogenesis.
• Caffeine — temporary antagonism of the adenosine brake; hormetic only when Fuel / Circadian / Strength can support higher throughput and recovery follows.

Nested buffers across timescales: phosphocreatine (seconds), adenine nucleotides/adenosine (minutes–hours), glycogen (hours), lipid stores (days), NAD⁺/NADH redox parallel. Hacking one receptor without recharging the stack is dashboard theater.

8. Adenosine as primary energy-stress signal

From the adenosine essay: adenosine is not primarily a sleep molecule, neuromodulator, or cardiovascular dilator. Those are downstream roles. At its core it is the most direct, evolutionarily conserved extracellular and intracellular signal of ATP breakdown and energy shortfall — the messenger that the cell’s engine is under load.

When ATP is hydrolyzed to meet demand, the adenine nucleotide pool shifts. AMP rises. Adenosine is generated from AMP by 5′-nucleotidases and exported. Extracellular adenosine binds A1 and A2A receptors; intracellular AMP activates AMPK. The two arms are linked but not identical. Together they constitute the cell’s real-time energy-stress dashboard and the initiating trigger for adaptive programs that restore capacity: mitophagy of damaged mitochondria and biogenesis of new ones via AMPK → ULK1, mTOR restraint, and PGC-1α (with SIRT1 when NAD⁺ is available). Adenosine/AMP and NAD⁺/NADH are twin currencies — adenine side and redox side — converging on the same remodeling axis.

Via A1 receptors adenosine inhibits wake-promoting neurons, reduces firing rates, and lowers metabolic demand. Fatigue is the organism-level readout of this molecular signal — the high-frequency dashboard made conscious. The brake exists because intermittent high-demand states followed by enforced rest are the ancestral pattern under which mitochondrial quality control evolved. Continuous high output without recovery was not selected for.

Rest, naps, and sleep recharge adenine ratios as ATP regenerates and extracellular adenosine clears. Circadian architecture protects the nocturnal window of mitophagy and biogenesis. Hormesis requires recovery: intermittent adenosine rise followed by rest, nutrient repletion, and circadian alignment yields more and better mitochondria; chronic, mistimed, or blocked signal without recovery yields compensatory pathology labeled disease. Caffeine, by temporarily occupying receptors, amplifies the underlying adenosine rise and intensifies hormetic demand — benefit or harm is determined by the quality of the recovery phase that follows (§9).

See also: Brain Sage’s memory claim fits the same causal direction — energetic capacity enables and constrains the structural configurations we call memory; structures do not create capacity. See Sage — Brain.

On Sage — Adenosine.

9. Caffeine: temporary override of the adenosine brake

From the caffeine essay: caffeine is not primarily a drug that “stimulates” a tired organism. It is an ancestral metabolic lever — structurally nearly identical to adenosine — that temporarily removes a conserved brake on cellular and systemic energy throughput. When used in alignment with persistence and EnSurf Fuel / Circadian / Strength, it can amplify mitochondrial flexibility, entrain rather than disrupt diurnal rhythms, and potentiate hormetic loading. When used as a chronic crutch for mismatched fuel, light, or movement, it becomes another source of compensatory stress.

At typical dietary concentrations the dominant action is adenosine-receptor antagonism; PDE inhibition and ryanodine-receptor effects appear mainly at higher exposures. Caffeine does not create energy; it temporarily removes the extracellular signal that would otherwise force demand reduction. Whether that removal is productive depends on whether underlying mitochondrial capacity and fuel environment can support higher throughput. Catecholamine-mediated lipolysis, cAMP amplification, and AMPK/CaMK/PGC-1α adjacency favor biogenesis when the stimulus is repeated under recovery. The phosphocreatine shuttle buffers extra demand; creatine loading and acute caffeine around training are complementary timescales in the same energy-charge network (not a Surfer shopping list).

Circadian gating: morning use after the cortisol awakening response has begun to decline tends to reinforce diurnal slope; evening use more readily elevates evening cortisol and fragments sleep. Population associations of moderate coffee intake with lower mortality are consistent with net benefit under coherent systems and with broader coffee-matrix polyphenols — they do not prove every individual should consume caffeine, and they do not authorize late-night override of sleep debt.

Caveats from the essay: severe sleep debt, uncontrolled anxiety, certain arrhythmias, pregnancy, drug interactions, extreme slow CYP1A2 metabolizers, and advanced mitochondrial disease may experience net harm. This page does not invent a milligram protocol for Surfers; milligram ranges in the Sage essay stay hypothesis / n=1 research language under clinician context — not a Lessons dosing card.

10. Nicotine as energy-demand signal (hypothesis map — not Surfer Rx)

From the nicotine essay: nicotine is not primarily a stimulant, cognitive enhancer, or dependency molecule. Those are downstream roles. At its core it is a plant alkaloid that engages the endogenous nicotinic acetylcholine receptor (nAChR) system — an evolutionarily conserved interface linking energy status to arousal, autonomic mobilization, thermogenesis, anti-inflammatory protection of capacity, and mitochondrial quality-control programs. Exogenous nicotine does not invent new pathways; in my hypothesis, it hijacks and amplifies signals biology already uses to match expenditure and cognitive allocation to fluctuating ATP demand.

Ancestral coupling: intermittent loads (foraging, cold, threat, prolonged wakefulness) required feed-forward arousal and mobilization while energy charge was still adequate — beyond a simple adenosine brake. Much of native ACh signaling arrives as discrete, activity-dependent pulses rapidly cleared by acetylcholinesterase, alongside slower changes in background tone. nAChRs activate quickly and desensitize on continued occupancy; recovery of sensitivity requires an agonist-free interval. In my hypothesis, continuous high cholinergic tone without recovery was not what evolution selected for.

Mechanistic nest: in rodents, central nAChR stimulation can inhibit hypothalamic AMPK in certain circuits and activate sympathetic outflow to brown adipose tissue; nicotinic signaling also activates beige fat cells, and α7-mediated signaling suppresses inflammatory cytokine production, which in this hypothesis protects mitochondrial capacity. In aging male mice and in cultured cells, very low concentrations of nicotine enhanced NAMPT activity via SIRT1, raising NAD⁺; if this holds in people, it would support the redox side of the energy ledger. Nicotinic activation does not replace the adenosine dashboard; it modulates demand and recruitment of capacity. In this hypothesis, benefit or harm depends heavily on dose, timing relative to the daily energy-management waveform, the temporal profile of the signal, and the quality of recovery, as well as on the delivery form and on each person’s cardiovascular and dependence risk.

There is an older line of research that fits this picture, and I want to state it carefully. Studies in smokers and in nicotine-treated rats suggest that nicotine changes where fat goes, not only how much we eat. In rats given nicotine, lipoprotein lipase (LPL) — the enzyme that pulls fat out of the blood and into a tissue — fell in fat tissue and rose in heart muscle, while fat cells released more of their stored fat. In smokers, fat-tissue LPL fell after a glucose drink, where in non-smokers it rose. When smokers quit, fat-tissue LPL climbed, and the people with the most LPL activity gained weight fastest. Nicotine also seems to act on receptors in fat tissue itself to release stored fat. My hypothesis is that part of nicotine’s effect on weight is this redirection of fuel: less fat stored, more fat sent to muscle to be burned, and a rebound in storage when nicotine stops.

The same research carries a warning I do not want to blur. Fat cells that resist insulin’s storage signal do not make the whole body more insulin sensitive. In mice, nicotine’s push on fat cells raised circulating fatty acids and caused insulin resistance throughout the body. In people, smokers and long-term nicotine gum users are more insulin resistant than non-users, smokers’ insulin sensitivity improves soon after quitting, and smoking is linked to more type 2 diabetes. Smokers also tend to carry a larger share of their fat around the organs even while weighing less. So I read the leanness of smokers as a redirection of fuel that comes with a metabolic cost, not as a healthier metabolism. Most of this evidence comes from smoking rather than nicotine alone, and the human studies are small. Smoking remains harmful for reasons that have nothing to do with fat storage, nicotine without smoke still has cardiovascular and sleep effects, and none of this is a reason to start or continue any nicotine product.

Acute vs chronic: acute low-to-moderate exposure produces small improvements in alerting attention and some memory measures, with benefits clearer in impaired states than in healthy nonsmokers, and raises resting metabolic rate; chronic intermittent use confined to the active phase and paired with protected recovery is the only regime the essay treats as potentially adaptive; chronic continuous or high-dose / prolonged kinetic profiles produce tolerance, dependence risk, cardiovascular load, sleep disruption, and, in my hypothesis, erosion of capacity. Combusted tobacco and rapid high-peak forms carry additional toxicant burdens beyond nicotinic signaling — not collapsed into “nicotine = smoking.”

: the essay contains frugal-framework and n=1 language including low milligram ranges and delivery kinetics. This Sage cites the map (demand amplifier; phasic vs tonic; recovery required) and explicitly does not promote Surfer self-medication, dependence initiation, or a Coach dosing chapter. Dependence, pregnancy, cardiovascular disease, and adolescent brain risk belong with clinicians. Dashboard capture warning: hacking nAChRs without Fuel / Circadian / Strength recovery is the same error as chasing TSH alone.

11. Endocannabinoids as conservation and recovery signal

From the endocannabinoid essay: endocannabinoids are not primarily reward molecules, anti-inflammatory agents, psychoactive modulators, or sleep promoters. Those are downstream roles. The ECS — centered on anandamide (AEA) and 2-AG acting principally at CB1 — is an evolutionarily conserved interface linking energy status to conservation, storage allocation, protective dampening of demand, and recovery programs. Exogenous cannabinoids engage and amplify signals biology already uses to match intake, expenditure, and mitochondrial activity to fluctuating abundance and post-demand recovery need.

Critical intramitochondrial detail: CB1 on mitochondrial outer membranes (mtCB1) decreases intramitochondrial cAMP/PKA activity, reduces Complex I function, and thereby lowers local respiration and ATP production. Central and peripheral CB1 tone promotes orexigenic drive, lipogenesis, and reduced energy expenditure while suppressing AMPK and PGC-1α-linked biogenesis under chronic conditions. At physiological intermittent levels the system can limit inflammatory cytokine production and excitotoxic waste — preserving capacity under load.

Ancestral logic: after scarcity–surplus cycles the organism needed more than adenosine brake and nicotinic amplifier — a mechanism to promote intake when available, drive lipogenesis, suppress unnecessary thermogenesis, provide retrograde synaptic inhibition against runaway firing, and throttle mitochondrial output to match need. Adaptive only when intermittent and followed by recovery; chronic, mistimed, or continuous tone produces receptor downregulation, unresolved anabolic drive, reduced biogenesis, sleep fragmentation, and metabolic disease or dependence phenotypes.

this page is not a cannabis dosing guide, CBD shopping list, or medical-marijuana protocol. Exogenous cannabinoids remain clinical / legal / dependence-risk questions owned by licensed care and local law. Hypothesis claim: conservation/recovery signaling is real biology; receptor hacking without charge restoration is dashboard capture.

12. Alcohol adjacency (— not a Surfer drinking protocol)

Natural adjacency: Metabolic Hypothesis of Alcohol frames ethanol as a metabolic substrate that forces rapid unregulated NADH/NAD⁺ shift, acetaldehyde burden, ROS, and mitochondrial quality-control stress — not a nutrient and not a crude “toxin” slogan. A narrow contingent hormetic window exists in principle when redox/acetaldehyde signals stay sub-damaging and recovery follows; the window is too individual and easily exceeded to justify population “moderate drinking is healthy” claims. Observational J-curves are vulnerable to confounding; Mendelian randomization often attenuates apparent benefit.

Cited here because alcohol sits on the same multi-timescale dashboard logic (redox currency, cortisol/CAR timing of stressors, recovery separation) and because Fuel Lessons already name alcohol among jellyfish insults. No Surfer “morning hormetic drink” protocol, no NAC concurrent-buffer recipe as site guidance, no encouragement to drink for longevity.

13. Implications: engine stewardship beside specialty tools

• Foundational EnSurf-aligned terrain (hypothesis): fuel quality (minimize seed-oil PUFAs that peroxidize cardiolipin and impair ETC/redox signaling; include animal fats/proteins for bioavailable nutrients; fermented MACs for gut–mito support where appropriate), circadian alignment (morning light, consistent sleep/feeding windows to entrain mito rhythms and hormone pulses; protect nocturnal adenosine clearance and mitophagy), dynamic strength training (PGC-1α-driven biogenesis, mitophagy, myokine release). These address root insults more directly than isolated hormone modulators or continuous stimulant occupancy as first resort.
• Energy-signal hygiene (hypothesis, not Rx): prefer intermittent demand and protected recovery over chronic receptor occupancy; treat fatigue and sleep pressure as adaptive dashboards before overriding them; if caffeine is used, gate it to the solar day and pair with recovery; do not invent nicotine/cannabinoid Surfer protocols from this essay.
• Adjunctive metabolic support language (not a retail shopping list or Surfer dose schedule): bioenergetic proxies (grip, HRV/sleep metrics, CGM/ketone flexibility); time-restricted eating or ketogenic/carnivore phases as supervised terrain; cofactors supporting ETC and antioxidant defense (CoQ10, PQQ, B vitamins, magnesium, creatine) as research-adjacent support language in the essays — invitation to testing with a clinician, not self-experiment theater.
• Pharmaceuticals repositioned, not rejected: use judiciously for acute stabilization, bridging, or when rapid control is needed (severe hyperglycemia, myxedema, adrenal crisis, clear glandular failure), while prioritizing root restoration in chronic or functional settings where upstream interventions often reduce medication burden. Do not stop insulin, thyroid replacement, steroids, or GLP-1 agonists from a Sage page.

14. Testable orientation

• Restoring level 0–1 efficiency should normalize signaling tone, sensitivity, and resolution capacity — insulin sensitivity, leptin/thyroid economy, quieter HPA, healthier myokine/adipokine profiles, more coherent gut-peptide sensing, cleaner adenosine clearance and sleep architecture — as predictions, not trial verdicts already in hand.
• Stratify patients by mitochondrial function or metabolic flexibility (grip, sleep/HRV proxies, emerging assays such as PBMC respirometry or plasma MDPs) alongside conventional hormone panels and HOMA-IR.
• Intermittent vs chronic stimulant/cannabinoid occupancy should diverge on recovery metrics (sleep depth, next-day grip/HRV, training willingness) more than on acute “feel awake” screenshots — hypothesis to test, not a Surfer self-trial mandate.
• Longitudinal links from bioenergetic decline to incident endocrine disorders or pharmacotherapy resistance would strengthen causal inference; mito restoration should reduce chronic reliance on replacement or agonists in a subset — hypothesis to test, not a promise.

15. Limits of the claim

• Working hypothesis. Not a randomized-trial verdict that mitochondrial-first strategies outperform guideline endocrinology as monotherapy.
• True glandular destruction, pituitary failure, autoimmune storm, surgical absence, congenital defects, and oncologic endocrine disease remain specialty clocks — compensation language does not erase anatomy.
• Dependence, withdrawal, pregnancy, pediatric exposure, arrhythmia, and substance-use disorders override any hormesis framing — urgent clinical care.
• No dualism.

16. Conclusion: silence the fire alarm by addressing the fire

Cell signaling dysfunction, like atherosclerosis, cancer, aging, and immune dysregulation in this series, emerges most coherently as compensatory activation or recalibration of higher-level coordination when level 0–1 cellular persistence cannot be maintained. Acute signaling clears threats and restores local energy balance; chronic forms reflect persistent deficit, failed resolution, and distorted mitocrine/paracrine feedback. Nitric oxide joins that cluster as the local flux-matching gas (delivery, rationing, conduit protection) whose chronic misuse becomes scar. The energy-signal cluster makes the same claim on multiple timescales: adenosine reports charge and enforces recovery; caffeine temporarily lifts the brake; nicotine amplifies demand; endocannabinoids conserve and throttle; alcohol loads redox without earning a longevity slogan. Endocrinology and stimulant pharmacology reveal the same pattern: energy-stressed cells and glands sustain loops of hypersecretion, resistance, inappropriate tone, or chronic receptor occupancy that appear as primary “imbalance” but attempt resource mobilization, conservation, and persistence under duress.

The chronic endocrine or stimulant fire alarm is best quieted by addressing the mitochondrial fire — bioenergetic insufficiency — it evolved to signal and compensate for. Higher-level tools, including targeted hormone modulation and clinically supervised substance decisions, remain available as needed — not as first or sole resort when the terrain can still hear. Coach and Surfer give shorter versions. Endocrinology, addiction medicine, and primary care still own diagnosis, replacement clocks, dependence care, and acute rescue.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 30, 2026.

References

10. Nicotine as energy-demand signal

1. Jun H, Yu H, Gong J, et al., 2018. An immune-beige adipocyte communication via nicotinic acetylcholine receptor signaling. Nature Medicine 24(6):814-822. doi:10.1038/s41591-018-0032-8
2. Martínez de Morentin PB, Whittle AJ, Fernø J, et al., 2012. Nicotine induces negative energy balance through hypothalamic AMP-activated protein kinase. Diabetes 61(4):807-817. doi:10.2337/db11-1079
3. Borovikova LV, Ivanova S, Zhang M, et al., 2000. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405(6785):458-462. doi:10.1038/35013070
4. Wang H, Yu M, Ochani M, et al., 2003. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421(6921):384-388. doi:10.1038/nature01339
5. Yang L, Shen J, Liu C, et al., 2023. Nicotine rebalances NAD(+) homeostasis and improves aging-related symptoms in male mice by enhancing NAMPT activity. Nature Communications 14(1):900. doi:10.1038/s41467-023-36543-8
6. Sarter M, Parikh V, Howe WM, 2009. Phasic acetylcholine release and the volume transmission hypothesis: time to move on. Nature Reviews Neuroscience 10(5):383-390. doi:10.1038/nrn2635
7. Giniatullin R, Nistri A, Yakel JL, 2005. Desensitization of nicotinic ACh receptors: shaping cholinergic signaling. Trends in Neurosciences 28(7):371-378. doi:10.1016/j.tins.2005.04.009
8. Mineur YS, Abizaid A, Rao Y, et al., 2011. Nicotine decreases food intake through activation of POMC neurons. Science 332(6035):1330-1332. doi:10.1126/science.1201889
9. Hofstetter A, Schutz Y, Jéquier E, et al., 1986. Increased 24-hour energy expenditure in cigarette smokers. The New England Journal of Medicine 314(2):79-82. doi:10.1056/NEJM198601093140204
10. Sztalryd C, Hamilton J, Horwitz BA, et al., 1996. Alterations of lipolysis and lipoprotein lipase in chronically nicotine-treated rats. American Journal of Physiology 270(2 Pt 1):E215-E223. doi:10.1152/ajpendo.1996.270.2.E215
11. Facchini FS, Hollenbeck CB, Jeppesen J, et al., 1992. Insulin resistance and cigarette smoking. The Lancet 339(8802):1128-1130. doi:10.1016/0140-6736(92)90730-q
12. Eliasson B, Taskinen MR, Smith U, 1996. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation 94(5):878-881. doi:10.1161/01.cir.94.5.878
13. Bergman BC, Perreault L, Hunerdosse D, et al., 2012. Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes 61(12):3156-3166. doi:10.2337/db12-0418
14. Wu Y, Song P, Zhang W, et al., 2015. Activation of AMPKα2 in adipocytes is essential for nicotine-induced insulin resistance in vivo. Nature Medicine 21(4):373-382. doi:10.1038/nm.3826
15. Pan A, Wang Y, Talaei M, et al., 2015. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology 3(12):958-967. doi:10.1016/S2213-8587(15)00316-2
16. Godoy JA, Valdivieso AG, Inestrosa NC, 2018. Nicotine Modulates Mitochondrial Dynamics in Hippocampal Neurons. Molecular Neurobiology 55(12):8965-8977. doi:10.1007/s12035-018-1034-8
17. Meng TT, Wang W, Meng FL, et al., 2021. Nicotine Causes Mitochondrial Dynamics Imbalance and Apoptosis Through ROS Mediated Mitophagy Impairment in Cardiomyocytes. Frontiers in Physiology 12:650055. doi:10.3389/fphys.2021.650055
18. Benowitz NL, 2010. Nicotine addiction. The New England Journal of Medicine 362(24):2295-2303. doi:10.1056/NEJMra0809890
19. O'Hara BF, Edgar DM, Cao VH, et al., 1998. Nicotine and nicotinic receptors in the circadian system. Psychoneuroendocrinology 23(2):161-173. doi:10.1016/s0306-4530(97)00077-2
20. Ferguson SA, Kennaway DJ, Moyer RW, 1999. Nicotine phase shifts the 6-sulphatoxymelatonin rhythm and induces c-Fos in the SCN of rats. Brain Research Bulletin 48(5):527-538. doi:10.1016/s0361-9230(99)00033-7
21. Jaehne A, Loessl B, Bárkai Z, et al., 2009. Effects of nicotine on sleep during consumption, withdrawal and replacement therapy. Sleep Medicine Reviews 13(5):363-377. doi:10.1016/j.smrv.2008.12.003
22. Zhang L, Samet J, Caffo B, et al., 2006. Cigarette smoking and nocturnal sleep architecture. American Journal of Epidemiology 164(6):529-537. doi:10.1093/aje/kwj231
23. Davila DG, Hurt RD, Offord KP, et al., 1994. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. American Journal of Respiratory and Critical Care Medicine 150(2):469-474. doi:10.1164/ajrccm.150.2.8049831
24. Paradiso KG, Steinbach JH, 2003. Nicotine is highly effective at producing desensitization of rat alpha4beta2 neuronal nicotinic receptors. The Journal of Physiology 553(Pt 3):857-871. doi:10.1113/jphysiol.2003.053447
25. Heishman SJ, Kleykamp BA, Singleton EG, 2010. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology 210(4):453-469. doi:10.1007/s00213-010-1848-1
26. Newhouse PA, Potter A, Singh A, 2004. Effects of nicotinic stimulation on cognitive performance. Current Opinion in Pharmacology 4(1):36-46. doi:10.1016/j.coph.2003.11.001
27. Perkins KA, Epstein LH, Stiller RL, et al., 1989. Acute effects of nicotine on resting metabolic rate in cigarette smokers. The American Journal of Clinical Nutrition 50(3):545-550. doi:10.1093/ajcn/50.3.545
28. Henningfield JE, Keenan RM, 1993. Nicotine delivery kinetics and abuse liability. Journal of Consulting and Clinical Psychology 61(5):743-750. doi:10.1037//0022-006x.61.5.743
29. Benowitz NL, Burbank AD, 2016. Cardiovascular toxicity of nicotine: Implications for electronic cigarette use. Trends in Cardiovascular Medicine 26(6):515-523. doi:10.1016/j.tcm.2016.03.001
30. Pilegaard H, Saltin B, Neufer PD, 2003. Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. The Journal of Physiology 546(Pt 3):851-858. doi:10.1113/jphysiol.2002.034850
31. Jessen AB, Toubro S, Astrup A, 2003. Effect of chewing gum containing nicotine and caffeine on energy expenditure and substrate utilization in men. The American Journal of Clinical Nutrition 77(6):1442-1447. doi:10.1093/ajcn/77.6.1442
32. Benowitz NL, Hukkanen J, Jacob P 3rd, 2009. Nicotine chemistry, metabolism, kinetics and biomarkers. Handbook of Experimental Pharmacology (192):29-60. doi:10.1007/978-3-540-69248-5_2
33. Lunell E, Fagerström K, Hughes J, et al., 2020. Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff. Nicotine & Tobacco Research 22(10):1757-1763. doi:10.1093/ntr/ntaa068
34. Newhouse P, Kellar K, Aisen P, et al., 2012. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 78(2):91-101. doi:10.1212/WNL.0b013e31823efcbb
35. Chajek-Shaul T, Berry EM, Ziv E, et al., 1990. Smoking depresses adipose lipoprotein lipase response to oral glucose. European Journal of Clinical Investigation 20(3):299-304. doi:10.1111/j.1365-2362.1990.tb01859.x
36. Carney RM, Goldberg AP, 1984. Weight gain after cessation of cigarette smoking. A possible role for adipose-tissue lipoprotein lipase. The New England Journal of Medicine 310(10):614-616. doi:10.1056/NEJM198403083101002
37. Ferrara CM, Kumar M, Nicklas B, et al., 2001. Weight gain and adipose tissue metabolism after smoking cessation in women. International Journal of Obesity 25(9):1322-1326. doi:10.1038/sj.ijo.0801716
38. Andersson K, Arner P, 2001. Systemic nicotine stimulates human adipose tissue lipolysis through local cholinergic and catecholaminergic receptors. International Journal of Obesity 25(8):1225-1232. doi:10.1038/sj.ijo.0801654
39. Audrain-McGovern J, Benowitz NL, 2011. Cigarette smoking, nicotine, and body weight. Clinical Pharmacology & Therapeutics 90(1):164-168. doi:10.1038/clpt.2011.105

See the notice at the top of this page. Working hypothesis, not medical advice. Essay draws from grounded mechanisms in Cell Signaling Dysfunction, adenosine / nicotine / endocannabinoid / caffeine essays, Alcohol adjacency (education only), Nitric Oxide 2.0 nest, Thyroid, Serotonin adjacency, and Good Doctor as of 2026 — individual care requires personalized evaluation by a qualified physician.